Five Prime Therapeutics Inc
Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
Last updated:
Abstract:
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Status:
Application
Type:
Utility
Filling date:
4 Mar 2020
Issue date:
24 Sep 2020